NASDAQ · Healthcare · Drug Manufacturers—General
Biogen Inc. (BIIB)
As of Sep 25, 4:00 PM ET, Biogen (BIIB) last traded at $227.60, up 0.55% on the day. Its TickerHum research score is 67/100 (above average). It reported revenue of $9.94B for the twelve months ending 2026-03-31, up 1.2% year over year, with a 24.9% operating margin.
Ratings
- Valuation: 83/100 — Strongest input: free-cash-flow yield 7.2 %. Weakest: price / earnings (ttm) 24.5x.
- Growth: 24/100 — Strongest input: revenue growth (ttm, yoy) +1.2 %. Weakest: diluted eps growth (ttm, yoy) -8.1 %.
- Profitability: 68/100 — Strongest input: gross margin 117.1 %. Weakest: return on equity 7.4 %.
- Financial health: 73/100 — Strongest input: current ratio 3.06. Weakest: cash / long-term debt 0.54.
- Momentum: 80/100 — Strongest input: 1-year return +65.7 %. Weakest: 3-month return +5.4 %.
- Attention: 58/100 — Strongest input: headlines in the last 7 days 26. Weakest: volume vs 3-month average 0.9x.
- Risk: 76/100 — Strongest input: max drawdown (1y) -14.3 %. Weakest: annualised volatility (1y) 34.9 %.
- Data confidence: 88/100 — Strongest input: inputs available 100 %. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $9.94B | TTM ending 2026-03-31 · 10-Q |
| Revenue growth | 1.2% | TTM ending 2026-03-31 · 10-Q |
| Net income | $1.37B | TTM ending 2026-03-31 · 10-Q |
| Diluted EPS | $9.30 | TTM ending 2026-03-31 · 10-Q |
| Gross margin | 117.1% | FY ending 2020-12-31 · 10-K |
| Operating margin | 24.9% | TTM ending 2022-03-31 · 10-Q |
| Net margin | 13.8% | TTM ending 2026-03-31 · 10-Q |
| Free cash flow | $2.42B | TTM ending 2026-03-31 · 10-Q |
| Cash | $3.38B | as of 2026-03-31 · 10-Q |
| Long-term debt | $6.29B | as of 2026-03-31 · 10-Q |
| Debt / equity | 0.34 | as of 2026-03-31 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000875045).
Compare Biogen with its closest competitors
- Biogen vs Bristol-Myers Squibb (BIIB vs BMY) — Same industry (Drug Manufacturers—General); market cap 3.8x
- Biogen vs Pfizer (BIIB vs PFE) — Same industry (Drug Manufacturers—General); market cap 4.9x
- Biogen vs Gilead Sciences (BIIB vs GILD) — Same industry (Drug Manufacturers—General); market cap 5.6x
- Biogen vs Amgen (BIIB vs AMGN) — Same industry (Drug Manufacturers—General); market cap 6.7x
- Biogen vs Merck & Co. (BIIB vs MRK) — Same industry (Drug Manufacturers—General); market cap 11x
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.